samedan logo
 
 
 
spacer
home > ebr > spring 2008 > why is it still drug discovery?
PUBLICATIONS
European Biopharmaceutical Review

Why is it Still Drug Discovery?

Matthew Segall at the ADMET Division, BioFocus DPI, explores the balance between luck and judgement in drug discovery

Estimates for average costs and durations vary, but a reasonable approximation puts the typical duration for bringing a drug to market at 12-15 years (1) and the average cost at over $800 million (2). The reason for this is that the process is dominated by failure, with a high attrition rate of compounds and projects, even in the later and most expensive clinical phases. Therefore, the majority of the cost is associated with compounds and projects that never result in a marketed drug.

Pharmaceutical R&D is conventionally divided into three phases, as illustrated in Figure 1. Although the exact definitions of these phases may vary and the boundaries are blurred, they may broadly be described as; target discovery, drug discovery and drug development. In this article, we focus on the drug discovery phase for small molecule drugs – those with a molecular weight less than around 800Da.

DRUG DISCOVERY VERSUS DRUG DESIGN

It is interesting to note that the middle phase is termed drug discovery, which suggests a search for a solution among many possibilities and with a certain element of speculation. This is in contrast to a design process, which implies a rational process by which a small number of optimal solutions are constructed ab initio. The high attrition rates of the current state-of-the-art suggest that drug discovery has not yet become drug design. Why is this, given recent industry trends that have emphasised techniques such as ‘rational drug design’ (3), ‘structure-based drug design’ (4), and ‘de novo drug design’ (5)?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Matthew Segall is Senior Director of the ADMET group of BioFocus DPI. He has a MSc in Computation from the University of Oxford and a PhD in Theoretical Physics from the University of Cambridge, with three years postdoctoral experience in the Cavendish Laboratory pioneering the use of first principles quantum mechanical modelling in the study of biological systems. In 2001 he joined Camitro (UK) working on the development of predictive models of drug metabolism. Following a merger with ArQule, he led the informatics team in developing state-of-the-art intuitive ADME decision and visualisation tools, while continuing to work on quantum-based ADME models. After the Cambridge-based ADME group joined Inpharmatica in 2003, he led the In Silico Optimisation group in developing StarDropTM. Since January 2006, he has managed the ADME/PK business for BioFocus DPI (formerly Inpharmatica), which combines experimental and in silico approaches to ADME optimisation in drug discovery.
spacer
Matthew Segall
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement